Advancing T‑cell engagers addressing key efficacy and safety challenges

June 4, 2026

Duration: 35 min

Content

‍

▶️ Current challenges in T‑cell engager development

‍

▶️ Advantages of CD34⁺ reconstituted mouse models for assessment of TCEs

‍

▶️ Predictive efficacy and safety evaluation of TCEs using hCD3 mouse models

‍

Speaker

‍

Fabiane Sônego, PhD in Immunology and Pharmacology, is the Director of Preclinical Models and Services at genOway. She has extensive expertise in in vivo models for immuno-oncology and inflammation and a proven track record of supporting researchers in advancing translational research and accelerating drug development.

‍

Related products

Catalog product

genO-panhCD3

genO‑panhCD3 (humanized ε, δ and γ chains - hCD3edg) immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

‍

genO-BRGSF-HIS

genO‑BRGSF‑HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Custom product

No items found.

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe

T-cell engagers